Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$16.89
-3.2%
$19.33
$16.10
$43.76
$2.12B0.732.26 million shs1.95 million shs
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$53.51
$63.50
$11.52B1.152.00 million shsN/A
Grifols, S.A. stock logo
GRFS
Grifols
$8.23
+1.5%
$7.31
$5.79
$9.96
$5.66B0.441.15 million shs714,892 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$38.35
+1.2%
$53.05
$34.10
$173.25
$3.77B0.851.79 million shs4.24 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-3.15%-8.75%-3.43%-35.90%-58.41%
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+15.80%
Grifols, S.A. stock logo
GRFS
Grifols
+1.48%+2.36%+14.15%+3.65%+14.31%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.19%-4.10%-36.55%-64.11%-68.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.1167 of 5 stars
4.30.00.04.42.32.50.6
Catalent, Inc. stock logo
CTLT
Catalent
0.8891 of 5 stars
1.00.00.04.60.00.01.9
Grifols, S.A. stock logo
GRFS
Grifols
2.8697 of 5 stars
0.03.01.70.02.10.03.8
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7946 of 5 stars
4.42.00.04.23.22.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$39.89136.20% Upside
Catalent, Inc. stock logo
CTLT
Catalent
2.00
Hold$63.33-0.23% Downside
Grifols, S.A. stock logo
GRFS
Grifols
3.50
Strong BuyN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.83
Moderate Buy$122.61219.71% Upside

Current Analyst Ratings Breakdown

Latest APLS, GRFS, SRPT, and CTLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $41.00
5/22/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$40.00 ➝ $40.00
5/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$169.00 ➝ $84.00
5/14/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.00
5/9/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.00
5/9/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$41.00 ➝ $23.00
5/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$21.00 ➝ $18.00
5/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$28.00 ➝ $20.00
5/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$30.00 ➝ $26.00
5/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$55.00 ➝ $47.00
5/8/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$188.00 ➝ $85.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$775.84M2.74N/AN/A$1.64 per share10.30
Catalent, Inc. stock logo
CTLT
Catalent
$4.38B2.63$2.64 per share24.04$19.91 per share3.19
Grifols, S.A. stock logo
GRFS
Grifols
$7.21B0.78$0.86 per share9.54$12.55 per share0.66
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.23B1.69N/AN/A$9.19 per share4.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$528.63M-$1.79N/AN/AN/A-34.97%-103.11%-28.96%8/7/2025 (Estimated)
Catalent, Inc. stock logo
CTLT
Catalent
-$1.04B-$2.26N/A47.022.69-9.28%-0.66%-0.24%N/A
Grifols, S.A. stock logo
GRFS
Grifols
$64.20M$1.177.037.84N/AN/AN/AN/A7/28/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M-$2.6930.683.51N/A7.43%11.00%3.35%8/6/2025 (Estimated)

Latest APLS, GRFS, SRPT, and CTLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million
2/28/2025Q4 2024
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.37-$0.29+$0.08-$0.29$197.92 million$212.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
$0.364.37%N/A30.77%N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
1.91
4.36
3.73
Catalent, Inc. stock logo
CTLT
Catalent
1.38
2.51
1.96
Grifols, S.A. stock logo
GRFS
Grifols
1.11
2.26
0.79
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.93
3.84
3.03

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Catalent, Inc. stock logo
CTLT
Catalent
N/A
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
Catalent, Inc. stock logo
CTLT
Catalent
0.31%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million115.93 millionOptionable
Catalent, Inc. stock logo
CTLT
Catalent
16,900181.51 million180.95 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
26,300687.56 million686.25 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
84098.28 million88.17 millionOptionable

Recent News About These Companies

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?
Sarepta Can Start Dosing Elevidys Trial, UK Regulators Say
Sarepta Shares Higher After J.P. Morgan Note

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$16.89 -0.55 (-3.15%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$16.84 -0.05 (-0.27%)
As of 06:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Catalent stock logo

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Grifols stock logo

Grifols NASDAQ:GRFS

$8.23 +0.12 (+1.48%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.32 +0.09 (+1.09%)
As of 07:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$38.35 +0.45 (+1.19%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$38.95 +0.60 (+1.56%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.